Skip to content
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Endocrinology · Autoimmune Polyglandular Syndrome Type 1

Understanding Your APS-1 Diagnosis

At a Glance

APS-1, also called APECED, is usually caused by inherited changes in both copies of the AIRE gene. The immune system then loses tolerance to the body's own tissues, so endocrine problems, infections, rashes, and other symptoms may appear separately over many years.

Receiving a diagnosis of APS-1 (Autoimmune Polyglandular Syndrome Type 1), also known as APECED, often marks the end of a long and confusing search for answers [1]. This condition is exceptionally rare, and because its symptoms often appear one by one over several years, many families spend a long time on a “diagnostic odyssey” before the pieces finally fit together [2]. Understanding how this condition works at a biological level can help you make sense of why so many different parts of the body are affected and why your journey to a diagnosis may have been so complex.

It is completely normal to feel overwhelmed, scared, or even relieved to finally have a name for what you are experiencing. Connecting with a genetic counselor or a rare-disease patient support organization can be a vital step in navigating the emotional and practical impact of this lifelong diagnosis.

The Biology of “Self” and “Not-Self”

At the heart of APS-1 is a breakdown in a process called central immune tolerance [3]. Under normal circumstances, your immune system acts like an elite security force that can distinguish between “self” (your own healthy cells) and “not-self” (invaders like bacteria or viruses). This training happens in the thymus, a small organ in the chest.

Inside the thymus, a gene called AIRE (Autoimmune Regulator) acts as a master instructor [4]. It forces the cells in the thymus to display tiny samples of proteins from all over the body—such as proteins from the liver, lungs, or adrenal glands [5]. As young immune cells (T cells) develop, they are exposed to these samples. If a T cell mistakenly reacts to a “self” protein, the thymus identifies it as a threat and deletes it before it can enter the bloodstream [6].

In APS-1, mutations in the AIRE gene mean this master instructor cannot do its job properly [7]. Without those samples to learn from, the immune system never completely learns which cells belong to you. As a result, self-reactive T cells escape into your body and can eventually target your own organs [8].

Inheritance and Genetics

APS-1 is typically an autosomal recessive disorder [9]. This means that for a person to have the condition, they usually must inherit two changed (mutated) copies of the AIRE gene—one from each parent. Knowing the exact AIRE variant can help confirm the diagnosis and guide genetic counseling for relatives, but it is important to know that genotype does not reliably predict the exact organs or timing of future disease.

  • Carriers: Parents typically carry only one mutated copy and do not show any symptoms of the disease themselves.
  • Biallelic Mutations: When a child inherits two mutated copies (one from each parent), they develop the classic form of APS-1 [10].
  • Dominant-Negative Variants: In rarer cases, certain specific mutations in only one copy of the AIRE gene can cause a milder version of the condition that may appear later in life [9].

How Rare Is APS-1?

APS-1 is classified as an ultra-rare disease. Globally, it is estimated to affect approximately 1 in 90,000 to 200,000 people [11]. However, the condition is much more common in certain populations due to founder effects, where a specific genetic mutation is passed down through generations within a geographically or culturally isolated group [12].

Population Estimated Frequency
Global Average ~1 in 90,000 to 200,000 [11]
Finland ~1 in 25,000 [13]
Sardinia ~1 in 14,400 [13]
Iran (General Population) ~1 in 6,500 to 9,000* [11]

*Specific rates for the Iranian Jewish community are notably elevated compared to global averages [11][12].

Validating the “Diagnostic Odyssey”

It is very common for APS-1 to be misdiagnosed for years. This is because the “classic triad” of symptoms—chronic mucocutaneous candidiasis (persistent yeast infections), hypoparathyroidism (low calcium), and Addison’s disease (adrenal insufficiency)—rarely appear all at once [14]. In fact, only about 57% of patients eventually develop all three, and they often emerge years apart [14].

Recent research shows that many patients experience “non-triad” signs long before they meet the official diagnostic criteria [2]. These early clues can include:

  • Enamel Hypoplasia: Pitting or thinning of the tooth enamel in permanent teeth [15].
  • APECED Rash: A chronic, itchy, or hive-like rash that often appears in early childhood [16].
  • Intestinal Dysfunction: Chronic diarrhea or malabsorption issues [17].
  • Keratopathy: Inflammation or irritation of the clear front part of the eye (cornea) [18].

If you felt that your symptoms were dismissed or treated as isolated problems for years, your experience is validated by the medical literature. In some cases, patients have been treated for single issues, like adrenal failure, for over 25 years before the connection to APS-1 was finally made [1]. Recognizing these early signs and using expanded diagnostic criteria can now help clinicians cut the time to diagnosis significantly [19].

Common questions in this guide

What is APS-1, also called APECED?
APS-1 is a rare inherited autoimmune condition usually caused by changes in both copies of the AIRE gene. Because the immune system does not fully learn which tissues belong to the body, it may attack several organs and cause symptoms at different times.
How does a person inherit APS-1?
The classic form is usually autosomal recessive, meaning a person inherits one changed AIRE copy from each parent. Parents who carry one changed copy usually do not have symptoms. Rare dominant-negative AIRE variants in one copy can cause a milder form that begins later.
What are the early signs of APS-1?
The classic features are persistent yeast infections, low calcium from hypoparathyroidism, and adrenal insufficiency called Addison's disease. These may be preceded by enamel defects, a chronic itchy or hive-like rash, chronic diarrhea or malabsorption, or corneal inflammation. Symptoms often appear years apart, and not everyone develops all three classic features.
Why can it take years to diagnose APS-1?
APS-1 symptoms commonly appear one at a time rather than together, and the classic combination may not be present early. People may first be treated for separate problems such as yeast infections, low calcium, or adrenal insufficiency. Looking for non-classic clues and testing the AIRE gene can help connect the findings.
Can genetic testing confirm APS-1 and help my family?
Testing for changes in the AIRE gene can help confirm APS-1 and identify the inheritance pattern. A genetic counselor can explain what the result means for parents, siblings, children, and other relatives and whether testing or screening is appropriate. The exact variant does not reliably predict which organs will be affected or when symptoms will appear.
Will everyone with APS-1 develop the full classic triad?
No. Only about 57% of people with APS-1 eventually develop all three classic features: chronic mucocutaneous candidiasis, hypoparathyroidism, and Addison's disease. These problems can emerge years apart, so the absence of one feature early on does not necessarily rule out APS-1.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What specific mutations were found in my (or my child's) AIRE gene? Are they homozygous, compound heterozygous, or a dominant-negative variant?
  2. 2.Does the clinical picture include non-triad signs like enamel defects, chronic rashes, or intestinal issues that might have been present before the main diagnosis?
  3. 3.Given this diagnosis, should my immediate family members undergo genetic testing or screening for anti-interferon antibodies?
  4. 4.Are there specific specialists (e.g., endocrinologists, immunologists, dentists) who should be part of my care team given these results?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    Delay in the Diagnosis of APECED: A Case Report and Review of Literature from Iran.

    Jamee M, Mahdaviani SA, Mansouri D, et al.

    Immunological investigations 2020; (49(3)):299-306 doi:10.1080/08820139.2019.1671451.

    PMID: 31588815
  2. 2

    Redefined clinical features and diagnostic criteria in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy.

    Ferre EM, Rose SR, Rosenzweig SD, et al.

    JCI insight 2016; (1(13)).

    PMID: 27588307
  3. 3

    [Induction of central tolerance by the factor Aire: molecular and epigenetic regulation].

    Lopes N, Ferrier P, Irla M

    Medecine sciences : M/S 2015; (31(8-9)):742-7 doi:10.1051/medsci/20153108012.

    PMID: 26340833
  4. 4

    Novel Findings into AIRE Genetics and Functioning: Clinical Implications.

    De Martino L, Capalbo D, Improda N, et al.

    Frontiers in pediatrics 2016; (4()):86 doi:10.3389/fped.2016.00086.

    PMID: 27597936
  5. 5

    DNA breaks and chromatin structural changes enhance the transcription of autoimmune regulator target genes.

    Guha M, Saare M, Maslovskaja J, et al.

    The Journal of biological chemistry 2017; (292(16)):6542-6554 doi:10.1074/jbc.M116.764704.

    PMID: 28242760
  6. 6

    Autoimmune regulator and self-tolerance - molecular and clinical aspects.

    Abramson J, Husebye ES

    Immunological reviews 2016; (271(1)):127-40 doi:10.1111/imr.12419.

    PMID: 27088911
  7. 7

    AAV9-mediated AIRE gene delivery clears circulating antibodies and tissue T-cell infiltration in a mouse model of autoimmune polyglandular syndrome type-1.

    Almaghrabi S, Azzouz M, Tazi Ahnini R

    Clinical & translational immunology 2020; (9(9)):e1166 doi:10.1002/cti2.1166.

    PMID: 32994995
  8. 8

    The Role of Interferon-γ in Autoimmune Polyendocrine Syndrome Type 1.

    Oikonomou V, Smith G, Constantine GM, et al.

    The New England journal of medicine 2024; (390(20)):1873-1884 doi:10.1056/NEJMoa2312665.

    PMID: 38810185
  9. 9

    Approach to the patient with APS-1/APECED.

    Webb T, Pechacek J, Lionakis MS

    The Journal of clinical endocrinology and metabolism 2026; doi:10.1210/clinem/dgag282.

    PMID: 42460781
  10. 10

    Dominant-negative heterozygous mutations in AIRE confer diverse autoimmune phenotypes.

    Oftedal BE, Assing K, Baris S, et al.

    iScience 2023; (26(6)):106818 doi:10.1016/j.isci.2023.106818.

    PMID: 37235056
  11. 11

    Molecular and clinical characterization of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome (APECED) in Iranian non-Jewish patients: report of two novel AIRE gene pathogenic variants.

    Setoodeh A, Panjeh-Shahi S, Bahmani F, et al.

    Orphanet journal of rare diseases 2022; (17(1)):10 doi:10.1186/s13023-021-02170-z.

    PMID: 34991662
  12. 12

    Report of two siblings with APECED in Serbia: is there a founder effect of c.769C>T AIRE genotype?

    Fierabracci A, Lanzillotta M, Vorgučin I, et al.

    Italian journal of pediatrics 2021; (47(1)):126 doi:10.1186/s13052-021-01075-8.

    PMID: 34078422
  13. 13

    Type 1 Diabetes in Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy Syndrome (APECED): A "Rare" Manifestation in a "Rare" Disease.

    Fierabracci A

    International journal of molecular sciences 2016; (17(7)).

    PMID: 27420045
  14. 14

    Clinical, immunological, and genetic features in 938 patients with autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED): a systematic review.

    Sharifinejad N, Zaki-Dizaji M, Tebyanian S, et al.

    Expert review of clinical immunology 2021; (17(8)):807-817 doi:10.1080/1744666X.2021.1925543.

    PMID: 33957837
  15. 15

    Case Report: Dental Findings Can Aid in Early Diagnosis of APECED Syndrome.

    Brenchley L, Ferré EMN, Schmitt MM, et al.

    Frontiers in dental medicine 2021; (2()) doi:10.3389/fdmed.2021.670624.

    PMID: 38148990
  16. 16

    Early recognition of the APECED rash can accelerate the diagnosis of APECED.

    Ferré EMN, Lee CR, Lionakis MS

    Clinical immunology communications 2024; (5()):30-33 doi:10.1016/j.clicom.2024.03.001.

    PMID: 38560426
  17. 17

    Case Report: Severe Hypocalcemic Episodes Due to Autoimmune Enteropathy.

    Halabi I, Barohom MN, Peleg S, et al.

    Frontiers in endocrinology 2021; (12()):645279 doi:10.3389/fendo.2021.645279.

    PMID: 34194389
  18. 18

    Early-onset hypoparathyroidism and chronic keratitis revealing APECED.

    Mezgueldi E, Bertholet-Thomas A, Milazzo S, et al.

    Clinical case reports 2015; (3(10)):809-13 doi:10.1002/ccr3.354.

    PMID: 26509012
  19. 19

    Performance of expanded diagnostic criteria for APECED in independent cohorts and implications for earlier diagnosis.

    Ferré EM, Pechacek J, Schmitt MM, et al.

    JCI insight 2026; (11(14)).

    PMID: 42484378

This page explains APS-1 biology, inheritance, and diagnostic clues for informational purposes only and does not constitute medical advice. Speak with your endocrinologist, immunologist, or genetic counselor about your or your child's care.

Get notified when new evidence is published on Autoimmune polyendocrinopathy type 1.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.